ADH-6 |
Katalog-Nr.GC64235 |
ADH-6 ist eine Tripyridylamid-Verbindung. ADH-6 hebt die Selbstorganisation der aggregationskernbildenden SubdomÄne von mutiertem p53 DBD auf. ADH-6 zielt auf mutierte p53-Aggregate in menschlichen Krebszellen ab und dissoziiert sie, wodurch die transkriptionelle AktivitÄt von p53 wiederhergestellt wird, was zu Zellzyklusarrest und Apoptose fÜhrt. ADH-6 hat das Potenzial fÜr die Erforschung von Krebserkrankungen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2227429-65-2
Sample solution is provided at 25 µL, 10mM.
ADH-6 is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53’s transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 has the potential for the research of cancer diseases[1].
[1]. Palanikumar L, et al. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Nat Commun. 2021;12(1):3962.
Average Rating: 5
(Based on Reviews and 38 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *